CombiMatrix Names Trilochan Sahoo, M.D., Director of Cytogenetics
09 Abril 2014 - 5:00AM
CombiMatrix Corporation (Nasdaq:CBMX), a molecular diagnostics
company specializing in DNA-based testing services for
developmental disorders and cancer diagnostics, today announced
that Trilochan Sahoo, M.D. FACMG, has recently joined the Company
as Director of Cytogenetics. Dr. Sahoo will report to Wes Tyson,
M.D., Chief Medical Officer of CombiMatrix.
Dr. Sahoo, 50, has spent most of his career involved in the
development, evaluation and implementation of microarray-based
technologies, especially as used as an important diagnostic tool in
clinical cytogenetics and genomics. Prior to coming to CombiMatrix,
Dr. Sahoo was Senior Director, Clinical Cytogenetics, at the Quest
Diagnostics Nichols Institute, located in San Juan Capistrano,
California.
"We are very pleased with the high caliber of physician talent
that we have added to the CombiMatrix team in the past few weeks,"
President and CEO Mark McDonough said. "Dr. Tyson and Dr. Sahoo are
well-published individuals who bring outstanding expertise in
developmental disorders and prenatal pathology to our already
strong medical team. Now that we have built out our medical
organization, we will continue to hire sales talent in the second
quarter of 2014 and complete our 'post funding' expansion from 6 to
15 field sales representatives by end of June 2014, in order to
capitalize on the outstanding opportunity in microarray-based
prenatal diagnostics that is in front of us."
Dr. Sahoo has written more than 60 published research papers,
most of them in the field of molecular cytogenetics, which is the
study of hereditary diseases and abnormalities through cytology
(the study of cells) and genetics (the science of heredity).
From 2008-2010, Dr. Sahoo was Laboratory Director for Signature
Genomic Laboratories LLC, an array-based comparative genomic
hybridization diagnostic laboratory located in Spokane, Washington.
From 2005-2008, Dr. Sahoo was Assistant Director, Kleberg
Cytogenetics Laboratory, Medical Genetics Laboratories at the
Baylor College of Medicine.
Dr. Sahoo received a Bachelor of Medicine, Bachelor of Surgery
(MBBS) degree from S.C.B. Medical College at Utkal University in
Cuttack, India. He received his Doctor of Medicine (M.D.) degree
from Christian Medical College & Hospital in Vellore, India,
and received his certification from the American Board of Genetics
in Clinical Cytogenetics while at the Baylor College of
Medicine.
About CombiMatrix Corporation
CombiMatrix Corporation provides valuable molecular diagnostic
solutions and comprehensive clinical support to foster the highest
quality in patient care. CombiMatrix specializes in miscarriage
analysis, prenatal testing and pediatric genetics, offering
DNA‑based testing for the detection of genetic abnormalities beyond
what can be identified through traditional methodologies.
CombiMatrix performs genetic testing utilizing a variety of
advanced cytogenomic techniques, including chromosomal microarray,
standardized and customized fluorescence in situ hybridization
("FISH") and high-resolution karyotyping. CombiMatrix is dedicated
to providing high-level clinical support for healthcare
professionals in order to help them incorporate the results of
complex genetic testing into patient-centered medical decision
making. Additional information about CombiMatrix is available at
www.combimatrix.com or by calling 1-800-710-0624.
Safe Harbor Statement under the Private Securities
Litigation Reform Act of 1995
This press release contains forward-looking statements within
the meaning of the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
based upon our current expectations, speak only as of the date
hereof and are subject to change. All statements, other than
statements of historical fact included in this press release, are
forward-looking statements. Forward-looking statements can often be
identified by words such as "anticipates," "expects," "intends,"
"plans," "goal," "predicts," "believes," "seeks," "estimates,"
"may," "will," "should," "would," "could," "potential," "continue,"
"ongoing," "objective," similar expressions, and variations or
negatives of these words. These forward-looking statements are not
guarantees of future results and are subject to risks,
uncertainties and assumptions that could cause our actual results
to differ materially and adversely from those expressed in any
forward-looking statement. The risks and uncertainties referred to
above include, but are not limited to: our ability to successfully
expand the base of our customers and strategic partners, add to the
menu of our diagnostic tests in both of our primary markets,
develop and introduce new tests and related reports, optimize the
reimbursements received for our testing services, and increase
operating margins by improving overall productivity and expanding
sales volumes; our ability to successfully accelerate sales, allow
access to samples earlier in the testing continuum, steadily
increase the size of our customer rosters in both developmental
medicine and oncology; our ability to attract and retain a
qualified sales force; rapid technological change in our markets;
changes in demand for our future products; legislative, regulatory
and competitive developments; general economic conditions; and
various other factors. Further information on potential
factors that could affect our financial results is included in our
Annual Report on Form 10-K, Quarterly Reports of Form 10-Q, and in
other filings with the Securities and Exchange Commission. We
undertake no obligation to revise or update publicly any
forward-looking statements for any reason, except as required by
law.
CONTACT: Company Contact:
Mark McDonough
President & CEO, CombiMatrix Corporation
Tel (949) 753-0624
Investor Contact:
Rene Caron
President, Allen & Caron
Tel (949) 474-4300
rene@allencaron.com
Media Contact:
Len Hall
Vice President, Media Relations, Allen & Caron
Tel (949) 474-4300
len@allencaron.com
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2024 a Jul 2024
Combimatrix Corp. (MM) (NASDAQ:CBMX)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024